Skip to main content
SpringerLink
Log in

Stem Cell Transplants for Hematopoietic Malignancies

  • Chapter
Molecular Biology of B-Cell and T-Cell Development

Part of the book series: Contemporary Immunology ((CONTIM))

  • 262 Accesses

Abstract

The purpose of this chapter is to identify clinical models or approaches that can be exploited to improve the curability of hematopoietic malignancies. The chapter begins by identifying tumor and host factors that the clinician must consider when identifying a specific clinical approach for a specific patient that ultimately will determine the curability of that particular tumor. The remaining sections in the chapter focus on strategies to approach hematopoietic malignancies, particularly those that may be either palliated or cured as a result of their inherent responsiveness to at least high-dose chemotherapy. These approaches include the goals, limitations, and timing of dose-intensive therapy, which are utilized to maximize tumor response and which may be required to provide curative therapy. Subsequently, there is a discussion of strategies to decrease the incidence of relapse. Such strategies include both ex vivo and in vivo mechanisms to eliminate minimal residual disease (e.g., autograft manipulation by purging or positive selection of normal stem cells; graft-vs-tumor effects, tumor vaccines, cytokine modulation). The authors hope that this chapter will suggest that early intensive therapy for patients with potentially curable malignancies should be a new paradigm for future clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Dastugue, N., Lafage-Pochitaloff, M., Leroux, D., Payen, C., Bernard, P., Huguet-Rigal, F., Stoppa, A., Marit, G., Molina, L., Michallet, M., et al. (1995) Prognostic significance of karyotype in de novo adult acute myeloid leukemia. The BGMT Group Leukemia 9, 1491–1498.

    PubMed  CAS  Google Scholar 

  2. Mrozek, K., Heinonen, K., de la Chapelle, A., and Bloomfield, C. (1997) Clinical significance of cytogenetics in acute myeloid leukemia. Sem. Oncol. 24, 17–31.

    CAS  Google Scholar 

  3. Armitage, J. (1997) The development of bone marrow transplantation as a treatment for patients with lymphoma-Twentieth Richard and Hinda Rosenthal Foundation Award Lecture. Clin. Cancer Res. 3, 829–836.

    PubMed  CAS  Google Scholar 

  4. Guba, S., Vesole, D., Jagannath, S., Bracy, D., Barlogie, B., and Tricot, G. (1997) Peripheral stem cell mobilization and engraftment in patients over age 60. Bone Marrow Transplant 20, 1–3.

    Google Scholar 

  5. Savarese, D., Hsieh, C.-C., and Steward, F. (1997) Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors. J. Clin. Oncol. 15, 2981–2995.

    PubMed  CAS  Google Scholar 

  6. Siu, L. and Tannock, I. (1997) Chemotherapy dose escalation: case unproven. J. Clin. Oncol. 15, 2765–2768.

    PubMed  CAS  Google Scholar 

  7. Biggs, J., Szer, J., Crilley, P., Atkinson, K., Downs, K., Dodds, A., Concannon, A., Avalos, B., Tutschka, P., Kapoor, N., Brodsky, I., Topolsky, D., Bulova, S., and Copelan, E. (1992) Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BuCy2. Blood 80, 1352–1357.

    PubMed  CAS  Google Scholar 

  8. Buckner, C., Clift, R., Appelbaum, F., and Thomas, E. (1992) A randomized study comparing two transplant regimens for CML in chronic phase. Blood 80, 72a.

    Google Scholar 

  9. Copeland, E., Grever, M., Kapoor, N., and Tutschka, P. (1989) Marrow transplantation following busulfan and cyclophosphamide for chronic myelogenous leukemia in accelerated or blastic phase. Br. J. Haematol. 71, 487–491.

    Article  Google Scholar 

  10. Santos, G. (1993) Busulfan and cyclophosphamide versus cyclophosphamide and total body irradiation for marrow transplantation in chronic myelogenous leukemia-a review. Leuk. Lymphoma 11, 201–204.

    Article  PubMed  Google Scholar 

  11. Petersen, F., Appelbaum, F., Hill, R., Fisher, L., Bigelow, C., Sanders, J., Sullivan, K., Bensinger, W., Witherspoon, R., Storb, R., Clift, R., Fefer, A., Priss, O., Weiden, P., Singer, J., Thomas, E., and Buckner, C. (1990) Autologous marrow transplantation for malignant lymphoma: a report of 101 cases from Seattle. J. Clin. Oncol. 8, 638–647.

    PubMed  CAS  Google Scholar 

  12. Philip, T., Armitage, J., Spitzer, G., Chauvin, F., Jagannath, S., Cahn, J., Colombat, P., Goldstone, A., Gorin, N., Flesh, M., Laporte, J.-P., Maraninchi, D.,Pico, J., Bosly, A., Anderson

    Google Scholar 

  13. C., Schots, R., Bion, P., Cabanillas, F., and Dicke, K. (1987) High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin’s lymphoma. N. Engl. J. Med. 316, 1493–1498.

    Article  Google Scholar 

  14. Vose, J., Armitage, J., Bierman, P., Weisenburger, D., Hutchins, M., Dowling, M., Moravec

    Google Scholar 

  15. D., Sorensen, S., Okerbloom, J., Bascom, G., Howe, D., Johnson, P., Langdon, R., Mailliard, J., Pevnick, W., Westberg, M., and Kessinger, A. (1989) Salvage therapy for relapsed or refractory non-Hodgkin’s lymphoma utilizing autologous bone marrow transplantation. Am. J. Med. 87, 285–288.

    Article  PubMed  Google Scholar 

  16. Jagannath, S., Vesole, D., Glenn, L., Crowley, J., and Barlogie, B. (1992) Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. Blood 80, 1666–1672.

    PubMed  CAS  Google Scholar 

  17. Tricot, G., Jagannath, S., Vesole, D., Crowley, J., and Barlogie, B. (1995) Relapse of multiple myeloma after autologous transplantation: survival outcome after salvage. Bone Marrow Transplant 16, 7–11.

    PubMed  CAS  Google Scholar 

  18. Govindarajan, R., Jagannath, S., Flick, J., Vesole, D., Sawyer, J., Barlogie, B., and Tricot, G. (1996) Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma. Br. J. Haematol. 95, 349–353.

    Article  PubMed  CAS  Google Scholar 

  19. Tricot, G., Jagannath, S., Vesole, D., Nelson, J., Tindle, S., Miller, L., Cheson, B., Crowley, J., and Barlogie, B. (1995) Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment of 225 patients. Blood 85, 588–596.

    PubMed  CAS  Google Scholar 

  20. Philip, T., Guglielmi, C., Hagenbeek, A., Somers, R., Van deer Lelie, H., Bron, D., Sonneveld, P., Gisselbrecht, C., Cahn, J., Harousseau, J., Coiffier, B., Biron, P., Mandelli, F., and Chauvin, F. (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N. Engl. J. Med. 333, 1540–1545.

    Article  PubMed  CAS  Google Scholar 

  21. Barlogie, B., Jagannath, S., and Tricot, G. (1998) Advances in the treatment of multiple myeloma, in Advances in Internal Medicine, vol. 43 ( Schrier, R., Abboud, F., Baxter, J., and Fauci, A., eds.), Mosby, St. Louis, MO, 279–320.

    Google Scholar 

  22. Barlogie, B., Jagannath, S., Vesole, D., Naucke, S., Cheson, B., Mattox, S., Bracy, D., Salmon, S., Jacobson, J., Crowley, J., and Tricot, G. (1997) Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 89, 789–793.

    PubMed  CAS  Google Scholar 

  23. Gribben, J. and Nadler, L. (1993) Monitoring minimal residual disease. Sem. Oncol. 20, 143–155.

    CAS  Google Scholar 

  24. Gribben, J., Neuberg, D., Freedman, A., Gimmi, C., Pesek, K., Barber, M., Saporito, L., Woo, S., Coral, F., Spector, N., Rabinowe, S., Grossbard, M., Ritz, J., and Nadler, L. (1993) Detection of polymerase chain reaction of residual cells with the bc1–2 translocation is associated with

    Google Scholar 

  25. increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 81 3449–3457.

    Google Scholar 

  26. Freedman, A., Gribben, J., Neuberg, D., Mauch, P., Soiffer, R., Anderson, K., Pandite, L., Robertson, M., Kroon, M., Ritz, J., and Nadler, L. (1996) High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 88, 2780–2786.

    PubMed  CAS  Google Scholar 

  27. Gribben, J., Neuberg, D., Barber, M., Moore, J., Pesek, K., Freedman, A., and Nadler, L. (1994) Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow. Blood 83, 3800–3807.

    PubMed  CAS  Google Scholar 

  28. Gorin, N., Aegerter, P., Auvert, B., Meloni, G., Goldstone, A., Burnett, A., Carella, A., Korbling, M., Herve, P., Maraninchi, D., Lowenberg, R., Verdonck, L., de Planque, M, Hermans, J., Helbig, W., Porcellini, A., Rizzoli, V., Alesandrino, E., Franklin, I., Reiffers, J., Colleselli, P., and Goldman, J. (1990) Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: a European survey of the role of marrow purging. Blood 75, 1606–1614.

    PubMed  CAS  Google Scholar 

  29. Douay, L., Hu, C., Giarratana, M., Bouchet, S., Conlon, J., Capizzi, R., and Gorin, N. (1995) Amifostine improves the antileukemic therapeutic index ofmafosfamide: implications for bone marrow purging. Blood 86, 2849–2855.

    PubMed  CAS  Google Scholar 

  30. Brenner, M., Rill, D., Moen, R., Krance, R., Heslop, H., Mirro, J. J., Anderson, W., and Ihle, J. (1994) Gene marking and autologous bone marrow transplantation [Review]. Ann. NY Acad. Sci. 716, 204–214.

    Article  PubMed  CAS  Google Scholar 

  31. Brenner, M., Rill, D., Moen, R., Krance, R., Mirro, J. J., Anderson, W., and Ihle, J. (1993) Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 341, 85, 86.

    Google Scholar 

  32. Heslop, H., Rooney, C., Rill, D., Krance, R., and Brenner, M. (1996) Use of gene marking in bone marrow transplantation. Cancer Detect. Prey. 20, 108–113.

    CAS  Google Scholar 

  33. Barnett, M., Eaves, C., Phillips, G., Kalousek, D., Klingemann, K., Landsdorp, P., Reece, D., Shepherd, J., Shaw, G., and Eaves, A. (1989) Successful autografting in chronic myeloid leukemia after maintenance of marrow in culture. Bone Marrow Transplant 4, 345–351.

    PubMed  CAS  Google Scholar 

  34. Coulombel, L., Kalousek, D., Eaves, C., Gupta, C., and Eaves, A. (1983) Long-term marrow culture reveals chromosomally normal hematopoietic progenitor cells in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. N. Engl. J. Med. 308, 1493–1498.

    Article  PubMed  CAS  Google Scholar 

  35. Udomsakdi, C., Eaves, C., Swolin, B., Reid, D., Barnett, M., and Eaves, A. (1992) Rapid decline of chronic myeloid leukemic cells in long-term culture due to a defect at the leukemic stem cell level. Proc. Natl. Acad. Sci. USA 89, 6192–6196.

    Article  PubMed  CAS  Google Scholar 

  36. Gazitt, Y., Reading, C., Hoffman, R., Wickrema, A., Vesole, D., Jagannath, S., Condino, J., Lee, B., Barlogie, B., and Tricot, G. (1995) Purified CD34+ Lin-Thy+ stem cells do not contain clonal myeloma cells. Blood 86, 381–389.

    PubMed  CAS  Google Scholar 

  37. Tricot, G. (1997) Multiparameter cell sorting of PBSC. VI International Workshop on Multiple Myeloma, Boston.

    Google Scholar 

  38. Ratanatharathorn, V., Uberti, J., Karanes, C., Abella, E., Lum, L., Momin, F., Cummings, G., and Sensenbrenner, L. (1994) Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin’ s lymphoma. Blood 84, 1050–1055.

    PubMed  CAS  Google Scholar 

  39. Takai, S., Tateno, M., Hirano, T., Kondo, N., Hirose, S., and Yoshiki, T. (1993) Increased IgE level as a marker of host-versus-graft disease: inhibition of this HVGD with a monoclonal antibody to IL-4. Cell. Immunol. 149, 1–10.

    Article  PubMed  CAS  Google Scholar 

  40. Ushiyama, C., Hirano, T., Miyajima, H., Okumura, K., Ovary, Z., and Hashimoto, H. (1995) Anti-IL-4 antibody prevents graft-versus-host disease in mice after bone marrow transplantation. J. Immunol. 154, 2687–2696.

    PubMed  CAS  Google Scholar 

  41. Weiss, L., Lubin, I., Factorowich, I., Lapidot, Z., Reich, S., Reisner, Y., and Slavin, S. (1994) Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. J. Immunol. 153, 2562–2567.

    PubMed  CAS  Google Scholar 

  42. Horowitz, M., Gale, R., Sondel, P., Goldman, J., Kersey, J., Kolb, H.-J., Rimm, A, Ringden, O., Rozman, C., Speck, B., Truitt, R., Zwaan, F., and Bortin, M. (1990) Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75, 555–562.

    PubMed  CAS  Google Scholar 

  43. Kolb, H.-J., Schattenberg, A., Goldman, J., Hertenstein, B., Jacobsen, N., Arcese, W., Ljungman, P., Ferrant, A., Verdonck, L., Niederwieser, D., van Rhee, F., Mittermueller, J., de Witte, T., Holler, E., and Ansari, H. for the European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. (1995) Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86, 2041–2050.

    PubMed  Google Scholar 

  44. Gluckman, E., Rocha, V., Boyer-Chammard, A., Locatelli, F., Arcese, W., Pasquini, R., Ortega, J., Souillet, G., Ferreira, E., Laporte, J.-P., Fernandez, M., and Chastang, C. (1997) Outcome of cord-blood transplantation from related and unrelated donors. N. Engl. J. Med. 337, 373–381.

    Article  PubMed  CAS  Google Scholar 

  45. Rubinstein, P., Carrier, C., Adamson, J., Migliaccio, A., Berkowitz, R., Kurtzberg, J., Scaradavou, A., and Stevens, C. (1996) New York Blood Center’s Program for unrelated placental/umbilical cord blood (PCB) transplantation: 243 transplants in the first 3 years. Blood 88, 142a.

    Google Scholar 

  46. Harris, D. (1994) Cord blood transplantation: implications for graft vs. host disease and graft vs. leukemia. Blood Cells 20, 560–565.

    PubMed  CAS  Google Scholar 

  47. Harris, D. (1995) In vitro and in vivo assessment of the graft-versus-leukemia activity of cord blood. Bone Marrow Transplant 15, 17–23.

    PubMed  CAS  Google Scholar 

  48. Keever, C., Abu-Hajir, M., Graf, W., McFadden, P., Prichard, P., O’Brien, J., and Flomberg, N. (1995) Characterization of the alloreactivity and anti-leukemia reactivity of cord blood mononuclear cells. Bone Marrow Transplant 15, 407–419.

    PubMed  CAS  Google Scholar 

  49. Charak, B., Brynes, R., Groshen, S., Chen, S.-C., and Mazumder, A. (1990) Bone marrow transplantation with interleukin-2 activated bone marrow followed by interleukin-2 therapy for acute myeloid leukemia in mice. Blood 76, 2187–2190.

    PubMed  CAS  Google Scholar 

  50. Heslop, H., Gottlieb, D., Bianchi, A., Meager, A., Prentice, H. Mehta, A., Hoffbrand, A., and Brenner, M. (1989) In vivo induction of gamma interferon and tumor necrosis factor by interleukin-2 infusion following intensive chemotherapy or autologous marrow transplantation. Blood 74 1374–1380.

    Google Scholar 

  51. Chrobak, L., Podzimek, K., Pliskova, L., Kerekes, Z., Zak, P., Voglova, J., Spacek, J., and Palicka, V. (1996) Serum soluble IL-2 receptor as a reliable and noninvasive marker of disease activity in patients with hairy cell leukemia. Neoplasm 43, 321–325.

    CAS  Google Scholar 

  52. Srivastava, M., Srivastava, A., and Srivastava, B. (1994) Soluble interleukin-2 receptor, soluble CD8 and soluble intercellular adhesion molecule-1 levels in hematologic malignancies. Leukemia Lymphoma 12, 241–251.

    Article  PubMed  CAS  Google Scholar 

  53. Upadhyaya, G., Guba, S., Sih, S., Feinberg, A., Talpaz, M., Kantarjian, H., Deisseroth, A., and Emerson, S. (1991) Interferon-alpha restores the deficient expression of the cytoadhesion molecule lymphocyte function antigen-3 by chronic myelogenous leukemia progenitor cells. J. Clin. Invest. 88, 2131–2136.

    Article  PubMed  CAS  Google Scholar 

  54. Selleri, C., Sato, T., Del Vecchio, L., Luciano, L., Barrett, A., Rotoli, B., Young, N., and Maciejewski, J. (1997) Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-a in chronic myelogenous leukemia. Blood 89, 957–964.

    PubMed  CAS  Google Scholar 

  55. Chauhan, D., Kharbanda, S., Ogata, A., Urashima, M., Teoh, G., Robertson, M., Kufe, D., and Anderson, K. (1997) Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood 89, 227–234.

    PubMed  CAS  Google Scholar 

  56. McCormack, E., Borzillo, G., Ambrosino, C., Mak, G., Hamablet, L., Qu, G., and Haley, J. (1997) Transforming growth factor-beta3 protection of epithelial cells from cycle-selective chemotherapy in vitro. Biochem. Pharmacol. 53, 1149–1159.

    Article  PubMed  CAS  Google Scholar 

  57. Bonini, C., Ferrari, G., Verzeletti, S., Servida, P., Zappone, E., Ruggieri, L., Ponzoni, S., Mavilio, F., Traversari, C., and Bordignon, C. (1997) HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276, 1719–1724.

    Article  PubMed  CAS  Google Scholar 

  58. Cohen, J., Boyer, O., Salomon, B., Onclercq, R., Charlotte, F., Bruel, S., Boisserie, G., and Klatzmann, D. (1997) Prevention of graft-versus-host disease in mice using a suicide gene expressed in T lymphocytes. Blood 89, 4636–4645.

    PubMed  CAS  Google Scholar 

  59. Munshi, N., Govindarajan, R., Drake, R., Ding, L., Iyer, R., Saylors, R., Kornbluth, J., Marcus, S., Chiang, Y., Ennist, D., Kwak, L., Reynolds, C., Tricot, G., and Barlogie, B. (1997) Thymidine kinase (TK) gene-transduced human lymphocytes can be highly purified, remain fully functional, and are killed efficiently with ganciclovir. Blood 89, 1334–1340.

    PubMed  CAS  Google Scholar 

  60. Munshi, N., Jagannath, S., Vesole, D., Desikan, K., Barlogie, B., and Tricot, G. (1996) Graft vs. myeloma effect: Thymidine kinase (TK) gene transduced lymphocyte infusion following allogeneic transplantation in myeloma. Blood 88, 244a.

    Google Scholar 

  61. Henslee-Downey, P., Abhyankar, S., Parrish, R., Pati, A., Goddar, K., Neglia, W., et al. (1997) Use of partially mismatched donors extends access to allogeneic marrow transplant. Blood 89, 3864–3872.

    PubMed  CAS  Google Scholar 

  62. Bloomfield, C., Lawrence, D., Arthur, D., Berg, D., Schiffer, C., and Mayer, R. (1994) Curative impact of intensification with high-dose cytarabine (HiDAC) in acute myeloid leukemia (AML) varies by cytogenetic group. Blood 84, 11la.

    Google Scholar 

  63. Cattoretti, G., Chang, C.-C., Cechova, K., Zhang, J., Ye, B., Falini, B., Louie, D., Offit, K., Chaganti, R., and Dalla-Favera, R. (1995) BCL-6 protein is expressed in germinal-center B cells. Blood 86, 45–53.

    Google Scholar 

  64. Clark, S., Mclaughlin, J., Crist, W., Changlin. R., and Witte, O. (1987) Unique forms of the abl tyrosine kinase distinguish Ph-positive CML from Ph-positive ALL. Science 235, 85–88.

    CAS  Google Scholar 

  65. deThe, H., Lavau, C., Marchio, A., Chomienne, C., Degos, L., and Dejean, A. (1991) The PML/RARa fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 66, 675–684.

    Article  CAS  Google Scholar 

  66. Erickson, P., Gao, J., Chang, K.-S., Look, T., Whisenant, E., Raimondi, S., Lasher, R., Trujillo, H., Rowley, H., and Drabkin, H. (1992) Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML 1 /ETO, with similarity to Drosophila segmentation gene, runt. Blood 80, 1825–1831.

    PubMed  CAS  Google Scholar 

  67. Haioun, C., Lepage, E., Gisselbrecht, C., Bastion, Y., Coiffier, B., Brice, P., Bosly, A., Dupriez, B., Nouvel, C., Tilly, H., Lederlin, P., Biron, P., Briere, J., Gaulard, P., and Reyes, F., for the Groupe d’Etudes des Lymphomes de l’Adulte. (1997) Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin’s lymphoma: updated results of the prospective study LNH87–2. J. Clin. Oncol. 15, 1131–1137.

    Google Scholar 

  68. Kakizuka, A., Miller, W., Umesono, K., Warrel, R., Frankel, S., Murty, V., Dmitrovsky, E., and Evans, R. (1991) Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARa with a novel putative transcription factor, PML. Cell 66, 663–674.

    Article  PubMed  CAS  Google Scholar 

  69. Keating, M., Cork, A., Broach, Y., Smith, T., Walters, R., McCredie, K., Trujillo, J., and Freireich, E. (1987) Toward a clinically relevant cytogenetic classification of acute myelogenous leukemia. Leukemia Res. 11, 119–133.

    Article  CAS  Google Scholar 

  70. Kelliher, M., Knott, A., Mclaughlin, J., Witte, O., and Rosenberg, N. (1991) Differences in oncogenic potency but not target cell specificity distinguish the two forms of the BCR/ABL oncogene. Mol. Cell. Biol. 11, 4710–4716.

    PubMed  CAS  Google Scholar 

  71. Levine, E., Arthur, D., Frizzera, G., Peterson, B., Hurd, D., and Bloomfield, C. (1985) There are differences in cytogenetic abnormalities among histologic subtypes of the non-Hodgkin’s lymphomas. Blood 66, 1414–1422.

    PubMed  CAS  Google Scholar 

  72. Liu, P., Tarle, S., Hajra, A., Claxton, D., Marlton, P., Freedman, M., Siciliano, M., and Collins, F. (1993) Fusion between transcription factor CBF13/PEBP213 and myosin heavy chain in acute myeloid leukemia. Science 261, 1041–1044.

    Article  PubMed  CAS  Google Scholar 

  73. Marosi, C., Koller, U., Koller-Weber, E., Schwarzinger, I., Schneider, B., Jager, U., Vahls, P., Nowotny, H., Pirc-Danoewinata, H., Steger, G., Kreiner, G., Wagner, B., Lechner, K., Lutz, D., Bettelheim, P., and Haas, O. (1992) Prognostic impact of karyotype and immunologic phenotype in 125 adult patients with de novo AML. Cancer Genet. Cytogenet. 61, 14–25.

    Article  PubMed  CAS  Google Scholar 

  74. Meyers, S., Downing, J., and Hiebert, S. (1993) Identification of AML-1 and the (8;21) translocation protein (AML-1/ETO) as sequence specific DNA binding proteins: the runt homology domain is required for DNA binding and protein-protein interactions. Mol. Cell. Biol. 13, 6336–6345.

    PubMed  CAS  Google Scholar 

  75. Miyoshi, H., Shimizu, K., Kozu, T., Maseki, N., Kaneko, Y., and Ohki, M. (1991) t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. Proc. Natl. Acad. Sci. USA 88 10,431–10,434.

    Google Scholar 

  76. Offit, K., Wong, G., Filippa, D., Tao, Y., and Chaganti, R. (1991) Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodgkin’s lymphoma: clinical correlations. Blood 77, 1508–1515.

    PubMed  CAS  Google Scholar 

  77. Rimokh, R., Berger, F., Delsol, G., Digonnet, I., Rouault, J., Tigaud, J., Gadoux, M., Coiffier, B., Bryon, C. B, P., and Magaud, J. (1994) Detection of the chromosomal translocation t(11;14) by polymerase chain reaction in mantle cell lymphomas. Blood 83, 1871–1875.

    Google Scholar 

  78. Swansbury, G., Lawler, S., Alimena, G., Arthur, D., Berger, R., Van Den Berghe, H., Bloomfield, C., de la Chappelle, A., Dewald, G., Garson, 0., Hagemeijer, A., Mitelman, F., Rowley, J., and Sakurai, M. (1994) Long-term survival in acute myelogenous leukemia: a second follow-up of the fourth international workshop on chromosomes in leukemia. Cancer Genet. Cytogenet. 73, 1–7.

    CAS  Google Scholar 

Download references

Authors
  1. Susan C. Guba
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bart Barlogie
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Pennsylvania, Philadelphia, PA, USA

    John G. Monroe

  2. California Institute of Technology, Pasadena, CA, USA

    Ellen V. Rothenberg

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer Science+Business Media New York

About this chapter

Cite this chapter

Guba, S.C., Barlogie, B. (1998). Stem Cell Transplants for Hematopoietic Malignancies. In: Monroe, J.G., Rothenberg, E.V. (eds) Molecular Biology of B-Cell and T-Cell Development. Contemporary Immunology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-4757-2778-4_25

Download citation

  • DOI: https://doi.org/10.1007/978-1-4757-2778-4_25

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-065-6

  • Online ISBN: 978-1-4757-2778-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation